Cover Image
Market Research Report

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 408079
Published Content info 86 Pages
Delivery time: 1-2 business days
Price
Back to Top
E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019
Published: June 10, 2019 Content info: 86 Pages
Description

Summary:

According to the recently published report 'E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019'; E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - E3 Ubiquitin-Protein Ligase X-linked inhibitor of apoptosis protein (XIAP) also known as inhibitor of apoptosis protein 3 (IAP3) and baculoviral IAP repeat-containing protein 4 (BIRC4) is a protein that stops apoptotic cell death. It modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. It acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. It inactivates CASP9 by keeping it in inactive state. It regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. It acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs).

The report 'E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019' outlays comprehensive information on the E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 4 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Breast Cancer, Cervical Cancer, Colorectal Cancer, Head And Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Lung Cancer, Malignant Mesothelioma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Pancreatic Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma and Relapsed Multiple Myeloma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)
  • The report reviews E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1878TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Overview
  • E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Companies Involved in Therapeutics Development
    • Adamed Sp zoo
    • Astex Pharmaceuticals Inc
    • Canget BioTekpharma LLC
    • Novartis AG
    • Noxopharm Ltd
    • Takeda Pharmaceutical Co Ltd
  • E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Drug Profiles
    • ADO-532 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASTX-660 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idronoxil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCL-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit XIAP for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit XIAP for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-3256336 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Dormant Products
  • E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Discontinued Products
  • E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2019: Noxopharm announces its DARRT-1 study fully enrolled
      • May 21, 2019: Debiopharm expands its immuno-oncology development program for Debio 1143, with the first IAP inhibitor/Nivolumab combination trial
      • May 20, 2019: LuPIN trial demonstrates high rates of response
      • May 02, 2019: DARRT treatment has lasting disease control at six months
      • Apr 16, 2019: Idronoxil confirmed as new immuno-oncology drug
      • Apr 10, 2019: Veyonda chemotherapy
      • Apr 01, 2019: Debiopharm releases results of its oncology drug candidate Debio 1143 at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA
      • Feb 21, 2019: Noxopharm to expedite Veyonda clinical program
      • Feb 06, 2019: Combination of Veyonda + Radiotherapy delivers clinical benefits
      • Jan 14, 2019: Noxopharm: Principal Investigator discusses LuPIN-1 Study
      • Dec 20, 2018: NOX Receives $3.26M Federal Govt R&D Rebate
      • Dec 11, 2018: Darrt-1 study advancing on basis of positive clinical data
      • Nov 29, 2018: NOX announces positive data from CEP-1 study of Veyonda
      • Nov 13, 2018: NOX to present clinical data at COSA Annual Meeting
      • Oct 22, 2018: Noxopharm makes key executive appointment
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Indications, H1 2019
  • Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019 (Contd..2), H1 2019
  • Number of Products under Investigation by Universities/Institutes, H1 2019
  • Products under Investigation by Universities/Institutes, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Pipeline by Adamed Sp zoo, H1 2019
  • Pipeline by Astex Pharmaceuticals Inc, H1 2019
  • Pipeline by Canget BioTekpharma LLC, H1 2019
  • Pipeline by Novartis AG, H1 2019
  • Pipeline by Noxopharm Ltd, H1 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Dormant Products, H1 2019
  • Dormant Products, H1 2019 (Contd..1), H1 2019
  • Dormant Products, H1 2019 (Contd..2), H1 2019
  • Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Top 10 Indications, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top